PCSK9 and peripheral arterial disease: Global treatment rates for PAD remain low, especially in low-sociodemographic index (SDI) regions, with substantial gaps in the prescription of antiplatelet therapy, statins, and proprotein convertase subtilisin/kexin type 9 inhibitors [31,32].